INT152215

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2008
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 14.13
Pain Relevance 0.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (FH) small molecule metabolic process (FH) lyase activity (FH)
cytoplasm (FH)
Anatomy Link Frequency
endothelial cells 1
germline 1
FH (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 20 92.96 High High
Pain 10 54.72 Quite High
Central nervous system 3 21.68 Low Low
addiction 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Renal Cancer 570 99.98 Very High Very High Very High
Renal Cell Carcinoma 43 99.98 Very High Very High Very High
Syndrome 454 99.68 Very High Very High Very High
Uterine Fibroids 87 98.52 Very High Very High Very High
Disease 269 97.92 Very High Very High Very High
Leiomyosarcoma 27 97.36 Very High Very High Very High
Carcinoma 39 96.34 Very High Very High Very High
Leiomyomatosis 33 95.96 Very High Very High Very High
Cancer 358 95.92 Very High Very High Very High
Hereditary Neoplastic Syndromes 6 93.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
renal cancer syndromes, renal cancers associated with HLRCC are aggressive [38].
HLRCC Binding (associated) of associated with syndrome and renal cancer
1) Confidence 0.41 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2581790 Disease Relevance 1.47 Pain Relevance 0.04
Their unique action is attributed to their effect directly on the tumor cells themselves, in part due to HIF downregulation, and on tumor endothelial cells by blocking proliferation and survival signals downstream of the VEGF receptor.23–25 One study has also shown that the benefits of mTOR inhibition may be greater in papillary renal carcinoma than in clear cell carcinoma; papillary subtype accounting for 10% to 15% of renal cell cancers.26 This is postulated to be due to HIF upregulation which is noted in patients with papillary renal cell carcinoma associated with fumarate–hydratase mutations.27
fumarate-hydratase Binding (associated) of in endothelial cells associated with cancer, carcinoma and renal cell carcinoma
2) Confidence 0.36 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004583 Disease Relevance 0.95 Pain Relevance 0
Some individuals diagnosed with HLRCC have an affected parent and some have HLRCC as the result of a de novo gene mutation.
HLRCC Binding (diagnosed) of
3) Confidence 0.32 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2581790 Disease Relevance 0.74 Pain Relevance 0
individuals with HLRCC who present with multiple cutaneous leiomyomas had renal
HLRCC Binding (individuals) of associated with uterine fibroids
4) Confidence 0.32 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2581790 Disease Relevance 1.66 Pain Relevance 0.05
that although some individuals diagnosed with HLRCC have an affected parent, the family history may appear to be negative because of failure to
HLRCC Binding (diagnosed) of
5) Confidence 0.32 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2581790 Disease Relevance 0.71 Pain Relevance 0
To date, six women with a germline mutation in FH have been reported
FH Binding (mutation) of in germline
6) Confidence 0.32 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2581790 Disease Relevance 0.77 Pain Relevance 0
Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer.
fumarate hydratase Binding (screening) of associated with leiomyomatosis and renal cancer
7) Confidence 0.30 Published 2008 Journal Cancer Genet. Cytogenet. Section Title Doc Link 18503824 Disease Relevance 0.97 Pain Relevance 0.05
HLRCC-associated
HLRCC Binding (associated) of
8) Confidence 0.10 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2495021 Disease Relevance 2.13 Pain Relevance 0
lesions prospectively identified in patients at risk for HLRCC should not be
HLRCC Neg (not) Binding (be) of
9) Confidence 0.10 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2495021 Disease Relevance 2.02 Pain Relevance 0
Patients with HLRCC, by contrast, develop aggressive
HLRCC Binding (Patients) of
10) Confidence 0.10 Published 2008 Journal Advances in Urology Section Body Doc Link PMC2495021 Disease Relevance 2.71 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox